What does PD-L1 positive or negative mean?

por Ribas, Antoni, Hu-Lieskovan, Siwen
Publicado 2016

Exosomes as a predictor tool of acquired resistance to melanoma treatment

por Goedert, Lucas, Koya, Richard, Hu-Lieskovan, Siwen, Ribas, Antoni
Publicado 2014

The dark side of immunotherapy

por Okwundu, Nwanneka, Grossman, Douglas, Hu-Lieskovan, Siwen, Grossmann, Kenneth F., Swami, Umang
Publicado 2021

First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma

por Wang, Xuechen, Haaland, Benjamin, Hu‐Lieskovan, Siwen, Colman, Howard, Holmen, Sheri L.
Publicado 2021

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma

por Homet Moreno, Blanca, Mok, Stephen, Comin-Anduix, Begonya, Hu-Lieskovan, Siwen, Ribas, Antoni
Publicado 2015

The role of biomarkers in personalized immunotherapy

por Sankar, Kamya, Ye, Jing Christine, Li, Zihai, Zheng, Lei, Song, Wenru, Hu-Lieskovan, Siwen
Publicado 2022

Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition

por Mok, Stephen, Tsoi, Jennifer, Koya, Richard C, Hu-Lieskovan, Siwen, West, Brian L, Bollag, Gideon, Graeber, Thomas G, Ribas, Antoni
Publicado 2015

Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics

por Davda, Jasmine, Declerck, Paul, Hu-Lieskovan, Siwen, Hickling, Timothy P., Jacobs, Ira A., Chou, Jeffrey, Salek-Ardakani, Shahram, Kraynov, Eugenia
Publicado 2019

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab

por Moser, Justin C., Chen, Danli, Hu‐Lieskovan, Siwen, Grossmann, Kenneth F., Patel, Shiven, Colonna, Sarah V., Ying, Jian, Hyngstrom, John R.
Publicado 2019

CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect

por Liu, Mingyue, Wang, Xu, Du, Xuexiang, Zhang, Yan, Ai, Chunxia, Hu-Lieskovan, Siwen, Li, Tianhong, Devenport, Martin, Liu, Yang, Zheng, Pan
Publicado 2022

Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration

por Hu-Lieskovan, Siwen, Braiteh, Fadi, Grilley-Olson, Juneko E., Wang, Xiao, Forgie, Alison, Bonato, Vinicius, Jacobs, Ira A., Chou, Jeffrey, Johnson, Melissa L.
Publicado 2021

Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma

por Pokorny, Rebecca, McPherson, Jordan P, Haaland, Benjamin, Grossmann, Kenneth F, Luckett, Carolyn, Voorhies, Benjamin Newell, Sageser, Daniel S, Wallentine, Jocelyn, Tolman, Zachary, Hu-Lieskovan, Siwen, Swami, Umang
Publicado 2021

Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis

por Allen, Clint T., Lee, Sunmin, Norberg, Scott M., Kovalovsky, Damian, Ye, Hong, Clavijo, Paul E., Hu-Lieskovan, Siwen, Schlegel, Richard, Schlom, Jeffrey, Strauss, Julius, Gulley, James L., Trepel, Jane, Hinrichs, Christian S.
Publicado 2019

Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1

por Poran, Asaf, Scherer, Julian, Bushway, Meghan E., Besada, Rana, Balogh, Kristen N., Wanamaker, Amy, Williams, Reid G., Prabhakara, Jasmina, Ott, Patrick A., Hu-Lieskovan, Siwen, Khondker, Zakaria S., Gaynor, Richard B., Rooney, Michael S., Srinivasan, Lakshmi
Publicado 2020

A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome

por Marsiglio, John, McPherson, Jordan P., Kovacsovics-Bankowski, Magdalena, Jeter, Joanne, Vaklavas, Christos, Swami, Umang, Grossmann, Douglas, Erickson-Wayman, Alyssa, Soares, Heloisa P., Kerrigan, Katie, Gibson, Berit, Doherty, Jennifer Anne, Hyngstrom, John, Hardikar, Sheetal, Hu-Lieskovan, Siwen
Publicado 2023

Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure

por Shin, Daniel, Garcia-Diaz, Angel, Zaretsky, Jesse, Escuin-Ordinas, Helena, Hu-Lieskovan, Siwen, Palaskas, Nicolaos J, Hugo, Willy, Komenan, Marie Sara, Chmielowski, Bartosz, Cherry, Grace, Berent-Maoz, Beata, Graeber, Thomas G, Lo, Roger, Comin-Anduix, Begonya, Ribas, Antoni
Publicado 2015

Antibody blockade of semaphorin 4D breaks down barriers to enhance tumoricidal immune infiltration and supports rational immunotherapy combinations

por Evans, Elizabeth E, Hu-Lieskovan, Siwen, Bussler, Holm, Torno, Sebold, Mallow, Crystal, Reilly, Christine, Scrivens, Maria, Klimatcheva, Ekaterina, Winter, Laurie A, Kirk, Renee, Howell, Alan, Balch, Leslie, Veeraraghavan, Janaki, Jonason, Alan S, Leonard, John E, Paris, Mark, Fisher, Terrence L, Ribas, Antoni, Smith, Ernest S, Zauderer, Maurice
Publicado 2015

Isolation and characterization of NY-ESO-1–specific T cell receptors restricted on various MHC molecules

por Bethune, Michael T., Li, Xiao-Hua, Yu, Jiaji, McLaughlin, Jami, Cheng, Donghui, Mathis, Colleen, Moreno, Blanca Homet, Woods, Katherine, Knights, Ashley J., Garcia-Diaz, Angel, Wong, Stephanie, Hu-Lieskovan, Siwen, Puig-Saus, Cristina, Cebon, Jonathan, Ribas, Antoni, Yang, Lili, Witte, Owen N., Baltimore, David
Publicado 2018

SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery

por Hu-Lieskovan, Siwen, Bhaumik, Srabani, Dhodapkar, Kavita, Grivel, Jean-Charles J B, Gupta, Sumati, Hanks, Brent A, Janetzki, Sylvia, Kleen, Thomas O, Koguchi, Yoshinobu, Lund, Amanda W, Maccalli, Cristina, Mahnke, Yolanda D, Novosiadly, Ruslan D, Selvan, Senthamil R, Sims, Tasha, Zhao, Yingdong, Maecker, Holden T
Publicado 2020

A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers

por Diab, Adi, Hamid, Omid, Thompson, John A., Ros, Willeke, Eskens, Ferry A.L.M., Doi, Toshihiko, Hu-Lieskovan, Siwen, Klempner, Samuel J., Ganguly, Bishu, Fleener, Catherine, Wang, Xiao, Joh, Tenshang, Liao, Ken, Salek-Ardakani, Shahram, Taylor, Carrie Turich, Chou, Jeffrey, El-Khoueiry, Anthony B.
Publicado 2022